LakeShore Biopharma Sets Shareholder Meeting to Vote on Going-Private Merger
LSBCF has more than doubled off its 52-week low of $0.028 on elevated volume (2.2× avg).
Summary
LakeShore Biopharma has scheduled an Extraordinary General Meeting for June 19, 2026, for shareholders to vote on the proposed going-private merger, which would delist the company and pay shareholders $0.09 per share.
Key Events · M&A and Partnerships · LSBCF
-
Shareholder Vote Scheduled
An Extraordinary General Meeting (EGM) is set for June 19, 2026, for shareholders to vote on the proposed going-private merger.
-
Merger Terms
The EGM will consider the Agreement and Plan of Merger, as amended on April 29, 2026, which proposes to take the company private at $0.09 per share.
-
Board Recommendation
The company's board of directors, based on a special committee's unanimous recommendation, advises shareholders to vote FOR the merger.
-
Delisting Imminent
If approved, the merger will result in LakeShore Biopharma becoming a privately held company, with its shares and warrants delisted from public markets.
Analysis · LSBCF · Life Sciences
This filing announces the date for the Extraordinary General Meeting where shareholders will vote on the proposed going-private merger. If approved, the company will delist, and shareholders will receive $0.09 per share, a price that was recently reduced. This is a critical procedural step towards the company's privatization, which will remove its shares from public trading.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LSBCF was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.03 to $2.80. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.